Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 0.84 |
| ▸ | PLG | P00747 | 15/20 | 0.84 |
| ▸ | F10 | P00742 | 7/20 | 0.84 |
| ▸ | F2 | P00734 | 6/20 | 0.84 |
| ▸ | ST14 | Q9Y5Y6 | 6/20 | 0.84 |
| ▸ | PLAT | P00750 | 4/20 | 0.84 |
| ▸ | HPN | P05981 | 2/20 | 0.84 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.84 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.84 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Upamostat SCHEMBL30912299 | 1.00 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL20674935 | 1.00 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| SCHEMBL30178270 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| SCHEMBL30343433 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| SCHEMBL20675070 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Hydrochloric Acid SCHEMBL31637457 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| SCHEMBL28534925 | 0.90 | PLAU (0.73) | PLAUPLGF10F2ST14 | |
| SCHEMBL17700973 | 0.90 | PLAU (0.73) | PLAUPLGF10F2ST14 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL1809303 | 0.89 | PLAU (0.67) | PLAUPLGF10F2ST14 | |
| SCHEMBL13727903 | 0.88 | PLAU (0.84) | PLAUPLGF10F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370206-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2025-07-29 | — | — | US | claimed |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD (IL) | 2024-04-04 | — | — | US | claimed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2020-01-28 | — | — | US | disclosed |
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD (IL) | 2018-05-10 | — | — | US | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-7951943-B2 | Method for preparing and purifying 3-hydroxyamidinophenylalanine compounds | WILEX AG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7951943-B2 | Method for preparing and purifying 3-hydroxyamidinophenylalanine compounds | WILEX AG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090099360-A9 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | WILEX AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099360-A9 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | WILEX AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080261998-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | WILEX AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080039626-A1 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | WILEX AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039626-A1 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | WILEX AG (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | RNMT, EIF2AK2, POLRMT | PLAU 1654/4885PLG 1720/4885F10 2270/4885 |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | EIF2AK2, RNMT, FBL | PLAU 1794/4885PLG 2036/4885F10 2391/4885 |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TPMT, KRAS, ACE | PLAU 3501/4885PLG 4797/4885F10 4154/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | PLAU 1816/4885PLG 1495/4885F10 1798/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | PLAU 3152/4885PLG 4780/4885F10 4229/4885 |
| US-20080261998-A1 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | PLAU, PLAUR, HPN | PLAU 1/4885PLG 6/4885F10 1217/4885 |
| US-20090099360-A9 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | PEPD, PAH, PRSS3 | PLAU 9/4885PLG 36/4885F10 893/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | PLAU 3328/4885PLG 4706/4885F10 3721/4885 |
| US-10463654-B2 | Combination therapies for treating cancer | TPMT, KRAS, ACE | PLAU 3501/4885PLG 4797/4885F10 4154/4885 |
| US-20080039626-A1 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | PEPD, PAH, PRSS3 | PLAU 9/4885PLG 36/4885F10 893/4885 |
| US-12370206-B2 | Therapy for inhibition of single-stranded RNA virus replication | EIF2AK2, RNMT, FBL | PLAU 1794/4885PLG 2036/4885F10 2391/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | PLAU 1816/4885PLG 1495/4885F10 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.